KINSHASA, DEMOCRATIC REPUBLIC OF CONGO — In a race against the clock, the Democratic Republic of Congo (DRC) has embarked on a clinical trial of experimental Ebola treatments as the outbreak in the country’s north-eastern region intensifies. Since the outbreak was declared on May 15, 2026, 1,460 confirmed cases have been reported, with 447 fatalities, translating to a fatality rate of 30. 6%.
The DRC is confronting a rare Ebola strain, the Bundibugyo variant, for which no specific treatments or vaccines are currently available.
In response, the Africa Centres for Disease Control and Prevention (Africa CDC) has requested $18 million to support the clinical trials.
The trial, involving patients who have tested positive for the virus, is a critical step to improve survival rates and bolster the country’s ability to respond to future outbreaks.
The World Health Organization (WHO) has expressed optimism about the experimental treatments, noting that the trial could take months and potentially involve more than 1,000 patients.
The WHO director — general, Tedros Adhanom Ghebreyesus, emphasized the importance of supportive care and close monitoring for participants, while also ensuring that post-trial access to the drugs is secured if they prove safe and effective.
The situation in the DRC is further complicated by the outbreak’s expansion, with daily confirmed cases averaging 38 over the past two weeks.
The epicentre remains in the north — eastern Ituri province, but cases have spread to North Kivu and South Kivu, and a case was confirmed in Kisangani, a major city far from the original epicentre, raising concerns about wider transmission.
The successful implementation of these experimental treatments could have significant implications not only for the DRC but also for the global community in the fight against Ebola outbreaks.
As the world watches with hope, the outcome of these trials is expected to contribute to the development of future strategies to combat the disease.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: rfi
Source: RFI
